Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249265 | 1.00 | HRH3 (0.53) | HRH3CYP2D6PKMALDH1A1LMNA | |
| SCHEMBL3249398 | 0.94 | HRH3 (0.53) | HRH3CYP2D6ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL3249393 | 0.94 | HRH3 (0.53) | HRH3CYP2D6ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL3264322 | 0.93 | HRH3 (0.54) | HRH3CYP2D6ALDH1A1LMNA | |
| SCHEMBL3243452 | 0.93 | HRH3 (0.54) | HRH3CYP2D6ALDH1A1LMNA | |
| SCHEMBL3243454 | 0.93 | HRH3 (0.54) | HRH3CYP2D6ALDH1A1LMNA | |
| SCHEMBL3251114 | 0.91 | HRH3 (0.51) | HRH3CYP2D6ALDH1A1LMNA | |
| SCHEMBL3251116 | 0.91 | HRH3 (0.51) | HRH3CYP2D6ALDH1A1LMNA | |
| SCHEMBL3261448 | 0.91 | HRH3 (0.51) | HRH3CYP2D6ALDH1A1LMNA | |
| SCHEMBL3245882 | 0.91 | HRH3 (0.53) | HRH3CYP2D6LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118089-B1 | INDOL-2-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-7507736-B2 | Indol-2-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080188484-A1 | INDOL-2-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188484-A1 | INDOL-2-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HRH4, HRH3, HRH2 | HRH3 2/4885CYP2D6 357/4885PKM 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.